Utilization of guideline-directed secondary prevention pharmacotherapy after CABG surgery is suboptimal, particularly regarding ACEI/ARB use, highlighting an opportunity for quality improvement.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Barry et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: